222 related articles for article (PubMed ID: 14985084)
1. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
2. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y
Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605
[TBL] [Abstract][Full Text] [Related]
3. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.
Yamamoto Y; Tsutsumi Y; Yoshioka Y; Nishibata T; Kobayashi K; Okamoto T; Mukai Y; Shimizu T; Nakagawa S; Nagata S; Mayumi T
Nat Biotechnol; 2003 May; 21(5):546-52. PubMed ID: 12665803
[TBL] [Abstract][Full Text] [Related]
4. [Creation of functional muteins using phage libraries for pharmacoproteomic-based drug discovery and development of DDS].
Yoshioka Y
Yakugaku Zasshi; 2004 Aug; 124(8):531-9. PubMed ID: 15297722
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
[TBL] [Abstract][Full Text] [Related]
6. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
[TBL] [Abstract][Full Text] [Related]
8. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
10. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.
Dai C; Fu Y; Li B; Wang Y; Zhang X; Wang J; Zhang Q
Sci China Life Sci; 2011 Feb; 54(2):128-38. PubMed ID: 21318482
[TBL] [Abstract][Full Text] [Related]
11. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
12. Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor.
Morishige T; Yoshioka Y; Inakura H; Tanabe A; Yao X; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2010 Mar; 393(4):888-93. PubMed ID: 20175993
[TBL] [Abstract][Full Text] [Related]
13. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
14. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
15. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
Youn YS; Lee KC
Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.
Dai C; Fu Y; Chen S; Li B; Yao B; Liu W; Zhu L; Chen N; Chen J; Zhang Q
Sci China Life Sci; 2013 Jan; 56(1):51-8. PubMed ID: 23314867
[TBL] [Abstract][Full Text] [Related]
17. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2.
Digilio G; Barbero L; Bracco C; Corpillo D; Esposito P; Piquet G; Traversa S; Aime S
J Am Chem Soc; 2003 Mar; 125(12):3458-70. PubMed ID: 12643708
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
[TBL] [Abstract][Full Text] [Related]
19. Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity.
Xiang J; Munegowda MA; Deng Y
Cancer Gene Ther; 2009 May; 16(5):430-8. PubMed ID: 19096444
[TBL] [Abstract][Full Text] [Related]
20. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y
Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
